Nabriva Therapeutics Plc
NBRV
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.55M
Close$
$5.13
261.3% upside
Current Fair Value
261.3% upsideUndervalued by 261.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.55 Million |
|---|---|
| Enterprise Value | $3.29 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-21.32 |
| Beta | 1.55 |
| Outstanding Shares | 3,201,000 |
Return
| Return on Equity | 1250.52% |
|---|---|
| Return on Assets | -223.87% |
| Return on Invested Capital | 1431.89% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.13 |
| Price to Book Ratio | -0.71 |
| Enterprise Value to Revenue | 0.09 |
| Enterprise Value to EBIT | -0.06 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | -0.12 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nabriva Therapeutics Plc
CEO: Theodore Schroeder